Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer

M Bauer,1 J Bryce,2 P Hadji11University of Marburg, Marburg, Germany; 2National Cancer Institute, Naples, ItalyAbstract: Postmenopausal women have an increased risk of osteopenia and osteoporosis due to loss of the bone-protective effects of estrogen. Disease-related processes may also contribute to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bauer M, Bryce J, Hadji P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5ee8db3a3ee946ffae223c84f4fcb28c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5ee8db3a3ee946ffae223c84f4fcb28c
record_format	dspace
spelling	oai:doaj.org-article:5ee8db3a3ee946ffae223c84f4fcb28c2021-12-02T03:47:44ZAromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer1179-1314https://doaj.org/article/5ee8db3a3ee946ffae223c84f4fcb28c2012-06-01T00:00:00Zhttp://www.dovepress.com/aromatase-inhibitor-associated-bone-loss-and-its-management-with-bisph-a10182https://doaj.org/toc/1179-1314M Bauer,1 J Bryce,2 P Hadji11University of Marburg, Marburg, Germany; 2National Cancer Institute, Naples, ItalyAbstract: Postmenopausal women have an increased risk of osteopenia and osteoporosis due to loss of the bone-protective effects of estrogen. Disease-related processes may also contribute to the risk of bone loss in postmenopausal women with breast cancer. One of the most common and severe safety issues associated with cancer therapy for patients with breast cancer is bone loss and the associated increase in risk of fractures. This paper reviews the recent literature pertaining to aromatase inhibitor (AI)-associated bone loss, and discusses suggested management and preventative approaches that may help patients remain on therapy to derive maximum clinical benefit. A case study is presented to illustrate the discussion. We observed that AIs are in widespread use for women with hormone receptor-positive breast cancer and are now recommended as adjuvant therapy, either as primary therapy or sequential to tamoxifen, for postmenopausal women. AIs target the estrogen biosynthetic pathway and deprive tumor cells of the growth-promoting effects of estrogen, and AI therapies provide benefits to patients in terms of improved disease-free survival. However, there is a concern regarding the increased risk of bone loss with prolonged AI therapy, which can be managed in many cases with the use of bisphosphonates and other interventions (eg, calcium, vitamin D supplementation, exercise).Keywords: aromatase inhibitors, bisphosphonates, bone loss, breast cancer, estrogenBauer MBryce JHadji PDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 91-101 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Bauer M Bryce J Hadji P Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
description	M Bauer,1 J Bryce,2 P Hadji11University of Marburg, Marburg, Germany; 2National Cancer Institute, Naples, ItalyAbstract: Postmenopausal women have an increased risk of osteopenia and osteoporosis due to loss of the bone-protective effects of estrogen. Disease-related processes may also contribute to the risk of bone loss in postmenopausal women with breast cancer. One of the most common and severe safety issues associated with cancer therapy for patients with breast cancer is bone loss and the associated increase in risk of fractures. This paper reviews the recent literature pertaining to aromatase inhibitor (AI)-associated bone loss, and discusses suggested management and preventative approaches that may help patients remain on therapy to derive maximum clinical benefit. A case study is presented to illustrate the discussion. We observed that AIs are in widespread use for women with hormone receptor-positive breast cancer and are now recommended as adjuvant therapy, either as primary therapy or sequential to tamoxifen, for postmenopausal women. AIs target the estrogen biosynthetic pathway and deprive tumor cells of the growth-promoting effects of estrogen, and AI therapies provide benefits to patients in terms of improved disease-free survival. However, there is a concern regarding the increased risk of bone loss with prolonged AI therapy, which can be managed in many cases with the use of bisphosphonates and other interventions (eg, calcium, vitamin D supplementation, exercise).Keywords: aromatase inhibitors, bisphosphonates, bone loss, breast cancer, estrogen
format	article
author	Bauer M Bryce J Hadji P
author_facet	Bauer M Bryce J Hadji P
author_sort	Bauer M
title	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
title_short	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
title_full	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
title_fullStr	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
title_full_unstemmed	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
title_sort	aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/5ee8db3a3ee946ffae223c84f4fcb28c
work_keys_str_mv	AT bauerm aromataseinhibitorassociatedbonelossanditsmanagementwithbisphosphonatesinpatientswithbreastcancer AT brycej aromataseinhibitorassociatedbonelossanditsmanagementwithbisphosphonatesinpatientswithbreastcancer AT hadjip aromataseinhibitorassociatedbonelossanditsmanagementwithbisphosphonatesinpatientswithbreastcancer
_version_	1718401631618334720

Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer

Ejemplares similares